Alphamab Oncology Executes HKD 0.94 Million Share Buyback, Lifts Treasury Stock to 8.09 Million Shares

Bulletin Express10-15

Alphamab Oncology (ALPHAMAB-B) disclosed that it repurchased 140,000 ordinary shares on 15 October 2026 through on-market transactions on the Hong Kong Stock Exchange. The shares were acquired at prices ranging from HKD 6.65 to HKD 6.79, translating into a volume-weighted average cost of HKD 6.74 per share and an aggregate consideration of approximately HKD 0.94 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 0.0145% to 966.30 million shares. Treasury shares increased to 8.09 million, while total issued shares remained unchanged at 974.38 million.

The repurchase forms part of the mandate approved on 12 June 2026, which authorises the company to buy back up to 96.85 million shares. Cumulative repurchases under this mandate now total 2.21 million shares, equivalent to 0.23% of the outstanding share count at the mandate date.

In line with Hong Kong listing regulations, Alphamab Oncology is restricted from issuing new shares or disposing of treasury shares until 14 November 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment